What is the aim of regenerative medicine and how can regenerative therapies help kidney patients in the future? Dr Olaf Schermeier, member of the Management Board responsible for Research and Development at Fresenius Medical Care, and Dr Jeffrey Lawson, CEO of Humacyte, Inc., a biotechnology and regenerative medicine company, answer these questions.
Imagine you could simply replace body parts that are injured or damaged, no matter whether it is from old age, illness or an accident! A new kidney, a functioning blood vessel, a healthy liver from the lab? It’s a great idea but deemed to be far from reality. Meanwhile, researchers all over the world are advancing the development of regenerative medicine.
“At present, chronic conditions are primarily treated with therapeutic approaches that aim to contain the illness or the symptoms,” explains Dr Olaf Schermeier, member of the management board at Fresenius Medical Care responsible for Research and Development. However, the vision of regenerative medicine is not only to treat medical symptoms, but to actually combat and heal their cause. “Regenerative medicine aims to permanently restore the physiological functions of the organ or body part,” Schermeier sums up.
We want to be at the forefront when technologies of this kind make the breakthrough.
Strategic investment: a win-win situation
To identify and assess trends in regenerative medicine at an early stage, Fresenius Medical Care relies on a combination of in-house research and external investment. Cooperation with innovative start-ups is a key element of this strategy. To this end, the company established Fresenius Medical Care Ventures in 2016, a venture capital fund that has set its strategic focus on investments in the regenerative medicine sector.
Both sides benefit from these strategic investments and alliances: whereas the start-ups bring fresh ideas, agile structures and innovative technologies to the table, Fresenius Medical Care contributes its experience in the health care industry, global relationships and market access. “We know how to bring new products successfully to market in the different healthcare systems,” says Schermeier. “In addition, we have a great deal of experience when it comes to developing a prototype through to series production.”
Blood vessels from the bioreactor
One example of a promising strategic partnership is the Company’s collaboration with Humacyte, Inc. The US-based biotechnology and regenerative medicine start-up has developed a revolutionary technology: humacyte grows blood vessels from donated smooth muscle cells in a bioreactor. Dr Jeffrey Lawson, CEO of Humacyte and a vascular surgeon, describes the benefits for dialysis patients: “Because our human acellular vessel no longer contains human cells, this vessel can be implanted in the patient without the risk of rejection.” Compared to synthetic transplants, the technology is expected to result in fewer complications, infections and fewer surgical procedures. “In the future, our blood vessels could potentially offer haemodialysis patients a safer and more durable vascular access, as well as a shorter catheter contact time depending upon the outcome of our investigation trials,” says Lawson.
In 2018, Fresenius Medical Care acquired a 19per cent stake in Humacyte as well as the global exclusive rights to market the biotechnologically manufactured Humacyl blood vessel for a combined investment of $150 million US dollars. “We were immediately impressed by the technology,” says Schermeier, explaining what lies behind the investment. The company aims to further develop the invention and bring it to global markets.
Humacyl is currently in phase III clinical trials in the US, Europe and Israel. Once these trials have been completed, the company intends to apply for regulatory approval in the US and Europe. The strategic partnership is a win for both companies. “Fresenius Medical Care gets new technology from us that will allow them to help improve vascular access for dialysis patients even further in the future,” says Lawson. “We at Humacyte have the opportunity of early and direct market entry.”
In the future, our blood vessels could potentially offer haemodialysis patients a safer and more durable vascular access.
A bridge between research and therapy
Fresenius Medical Care Ventures is constantly on the lookout for promising partners and investment opportunities. Fresenius Medical Care has also internally pooled its research activities in the field of regenerative medicine. In 2016, Fresenius Medical Care unveiled a new subsidiary, Unicyte AG, the result of long-term collaboration with the University of Turin in Italy. It was born from the idea that pioneering research results should not only be published in scientific publications, but also benefit patients as quickly as possible. “We wanted to build a bridge from academic research to developing actual therapies quickly,” says Schermeier.
Unicyte AG is an independent subsidiary of Fresenius Medical Care. The Swiss-based biotech company operates in the field of regenerative medicine, focusing on kidney and liver diseases as well as oncology and diabetes.
About regenerative medicine
Regenerative medicine is all about healing rather than repairing. The aim is to fully restore body functions that have been lost as a result of an accident or illness. It might even enable us to slow down our ageing process.
The new technologies include lab-grown biomaterials, tissue engineering and stem cell or gene therapies. The goal is always the same: to permanently restore the healthy, functional, original state of affected tissue as far as possible.
